The National Institutes of Health (NIH) is accepting applications for the program "Schizophrenia and Related Disorders during Mid- to Late-Life" (R21 Clinical Trial Optional). This funding opportunity seeks to support exploratory and developmental research to enhance understanding of the mechanisms and progression of schizophrenia and related disorders in individuals aged 35 and older. The program aims to identify potential targets for prevention and treatment strategies.

Eligible applicants include state and local governments, higher education institutions, tribal entities, nonprofits, small businesses, and for-profit organizations. The program does not require cost-sharing or matching funds. Applications are due by January 8, 2025, with additional cycles open until September 7, 2026.

Proposals should focus on novel, high-risk, high-reward studies that explore translational research questions related to mid- to late-life schizophrenia and its related disorders. Clinical trials are optional, providing flexibility in study design.